CVS

ACCE-researched
CVS Health Corporation Common Stock
Healthcare · Healthcare Plans · NYSE · United States
$87.60-1.40%
Market cap $112.0BNext earnings 2026-11-04Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$87.60+0.0%
confidence-weighted across 3 of 6 models
Now $87.60
$87.60
$42.31$187.92
HoldSilver70
Price vs fair value
4.4% above
-4.2% to fair value
ACCE score
65
out of 100
Analysts
86% buy
28 covering
P/E
23.1x
forward 10.3x
1-year return
+16.9%
Dividend yield
2.99%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 5 flags
  • high
    Massive insider selling
    Last 10 disclosed transactions show $323.70M in sales, zero buys - significant vote of no-confidence from insiders.
  • high
    Razor-thin net margin
    Net margin only 0.7% on a 0.3x P/S business; any revenue or cost shock could eliminate profitability entirely.
  • moderate
    Trailing P/E earnings distortion
    P/E of 45.7 vs forward 14.1 implies trailing earnings were severely depressed; +63.1% YoY growth may not be sustainable.
  • moderate
    Sequential revenue deceleration
    QoQ revenue growth of -5.0% despite +6.1% YoY suggests recent momentum is fading materially.
  • moderate
    Quality score very low
    ACCE Quality score of 30/100 flags weak fundamental quality despite the recent +22 score recovery from a low base of 43.
Reports in 43 days, last quarter beat by 0.4%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+16.6% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish86% buy · 28 covering analysts
● Strong buy 18● Buy 6● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 60% of peers
low 11.4x23.1xhigh 1236.3x
ROEbetter than 33% of peers
low -20%6%high 17%
Div yieldbetter than 100% of peers
low 0.0%3.0%high 3.0%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
ELVElevance Health Inc. Common Stock$88.8B18.111.1%0.731.7%-Compare
CIThe Cigna Group Common Stock$72.5B11.416.8%0.752.2%-Compare
HUMHumana Inc. Common Stock$45.5B35.86.9%0.700.9%-Compare
UNHUnitedHealth Group Incorporated Common Stock (DE)$338.9B24.214.1%0.832.4%-Compare
CNCCentene Corporation Common Stock$32.1B--20.4%0.870.0%-Compare
MOHMolina Healthcare Inc Common Stock$10.3B1236.3-0.2%0.930.0%-Compare

Sector report card

Where CVS ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 43 days, last quarter beat by 0.4%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
-8.3%
1 month
-5.8%
3 months
-13.8%
6 months
+21.4%
YTD
+10.4%
1 year
+16.9%

SEC filings

40 filings
August 2026
Aug 17
8-KCurrent reportPeriod 2026-08-13
Aug 5
10-QQuarterly reportPeriod 2026-06-30
Aug 5
8-KCurrent reportPeriod 2026-08-05
37 more filings + AI summaries on Investor+.INVESTOR